Test Price
2,800 AED✅ Home Collection Available
DYNC1H1 Gene Intellectual Disability, Autosomal Dominant Type 13 Genetic Test in UAE | 2800 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
Clinical Excellence Delivered to Your Doorstep
-
✓
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Next-Generation Sequencing (Cert: INT/EGQ/2509DA/3139). All variants interpreted against current ACMG and ClinGen standards.
-
✓
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain sample transport. VIP Mobile Phlebotomy available 8 AM – 11 PM daily, including weekends.
-
✓
Clinical Guidance: Complimentary telephonic post‑test result interpretation session with a DHA‑licensed genetic counsellor to contextualise findings within your family history.
-
✓
Insurance Verification: Direct billing assistance – send your insurance card via WhatsApp to +971 54 548 8731 for instant eligibility check.
Test Overview & Methodology
This single‑gene sequencing analysis interrogates the entire coding region of DYNC1H1 using Next‑Generation Sequencing (NGS) to detect pathogenic variants associated with Autosomal Dominant Intellectual Disability Type 13 (MRD13). Early molecular confirmation enables precise reproductive counselling and individualised developmental support.
| Feature | Our Test – UAE | Standard Overseas Lab |
|---|---|---|
| Sequencing Depth | ≥100x with full exon coverage, verified by Sanger for any low‑confidence variant | Often 20–30x; variants may not be reflex‑confirmed |
| Turnaround Time | 3–4 weeks from sample receipt, with online status tracking | 4–8 weeks; no patient portal |
| Variant Interpretation | Current ACMG and ClinGen standards, reviewed by board‑certified clinical geneticist | Often automated pipeline; no clinical context integration |
| Post‑Test Support | Free 20‑min genetic counsellor consultation + Arabic‑speaking advisors | No included support; additional cost for counselling |
Physician Insight & Safety Protocols
“Genetic testing for DYNC1H1 provides a molecular anchor for families navigating developmental challenges. I advise every patient to pair this result with a thorough clinical evaluation by a paediatric neurologist and a certified genetic counsellor. The report is a guide, not a verdict.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Safety Advisory – Medication Continuation
Important Medication Reminder
Do not discontinue any prescribed medication, including anticonvulsants or neurodevelopmental therapies, based solely on this genetic result without consulting your treating physician.
Exclusion Criteria & Emergency Red Flags
- This test is not intended for asymptomatic minors without a court‑issued genetic testing order, in compliance with UAE child protection and medical liability frameworks.
- Individuals without a documented clinical suspicion of intellectual disability or a confirmed family history of DYNC1H1‑related disorders should not undergo this test.
- Emergency red flag: If you or your child experiences acute psychological distress, suicidal ideation, or sudden behavioural deterioration after receiving results, seek immediate help at the nearest Emergency Department or call 998 for ambulance services.
Patient FAQ & Clinical Guidance
1. What does the DYNC1H1 gene test detect and how accurate is it?
This NGS test detects single nucleotide variants, small insertions and deletions, and copy number changes within the DYNC1H1 gene with 99.9% analytic sensitivity, enabling precise molecular diagnosis of autosomal dominant intellectual disability type 13. All pathogenic and likely pathogenic variants are reported according to current ACMG and AMP criteria. Benign variants are not disclosed. A negative result does not rule out other genetic disorders, so follow‑up clinical evaluation remains essential.
2. How is the sample collected and what is the turnaround time?
A single venipuncture blood sample (3 mL in EDTA tube) or a dried blood spot on an FTA card is collected at your home by a DHA‑licensed phlebotomist within 24 hours of booking, with results delivered in 3 to 4 weeks. You will receive a secure online report and a telephonic consultation slot automatically scheduled. FTA card collection is ideal for neonates and patients with difficult venous access.
3. Is this test covered by insurance and what are the age requirements?
We verify insurance coverage before the test via WhatsApp at +971 54 548 8731. The test is authorised for minors only when prescribed by a DHA‑licensed paediatrician or clinical geneticist, consistent with UAE medical liability regulations. Adults with personal suspicion or family history may self‑refer, but a pre‑test genetic counselling session is mandatory to review implications.
4. What support is available after receiving my results?
Every report includes a complimentary 20‑minute telephonic consultation with a DHA‑licensed genetic counsellor who will explain the findings, discuss recurrence risks, and guide you toward appropriate developmental or neurological follow‑up services. Arabic‑speaking advisors are available upon request.
UAE Regulatory & Data Privacy Adherence
Your Data, Your Rights – Fully Protected Under UAE Law
- Data Protection: All personal health information and genetic data are processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Medical Liability & Consent: This test is performed under the framework of Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring informed consent and patient safety at every step.
- Data Handling: Genetic data of minors is processed only with explicit parental consent and, where required, judicial authorisation. Results are encrypted and stored on UAE‑based secure servers.
Clinical & Logistical Metadata
| Test Name | DYNC1H1 Gene Sequencing – Autosomal Dominant Intellectual Disability Type 13 |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral whole blood (3 mL EDTA) or dried blood spot (FTA card) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger confirmation for low‑confidence variants |
| ICD-10-CM Code | F79 (Intellectual disability, unspecified), Z13.79 (Encounter for screening for other genetic/chromosomal anomalies), Z14.8 (Genetic susceptibility to other disease) |
| LOINC Code | 82939-5 (DYNC1H1 gene mutation detection) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians